FDA Acts to Prevent Shortage of Neonatal Starter Parenteral Nutrition
The US FDA has issued an immediately effective guidance to prevent a supply gap in starter parenteral nutrition for premature and critically ill newborns. The risk arose after two outsourcing facilities that made standardised neonatal starter PN announced they were closing permanently.
The guidance sets out temporary regulatory and enforcement priorities so that state-licensed pharmacies, federal facilities and outsourcing facilities can compound certain starter PN products. The FDA says it will keep monitoring supply and take further action if needed.
Key points
- Starter PN supplies IV nutrition to newborns who cannot be fed by mouth or tube.
- Children's hospitals raised concerns after two suppliers announced they were closing.
- The temporary compounding guidance took effect immediately.
- The FDA will continue to monitor supply.
What it means for you
NICU pharmacists everywhere depend on a small number of PN suppliers. The case shows why a backup plan for compounding neonatal PN is worth having in place.
FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.